Melphalan

Generic Name: Melphalan

Brand Names: Alkeran, Evomela, Phelinun, Pepaxti

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₈Cl_₂N_₂O_₂

CAS Number: 148-82-3

Unique Ingredient Identifier: Q41OR9510P

Background: Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.

Indication: Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.

Melphalan is a component of HEPZATO KIT, a liver-directed therapy indicated for the treatment of adults with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation.

Associated Conditions: Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Melphalan With BBBD in Treating Patients With Brain Malignancies

Phase 1

Terminated

Conditions: Lymphoma
Brain and Central Nervous System Tumors
Metastatic Cancer

Interventions: Drug: Melphalan

First Posted Date: 2005-11-15

Last Posted Date: 2017-04-21

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00253721

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Phase 2

Completed

Conditions: Neuroblastoma

Interventions: Biological: Filgrastim
Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Peripheral blood stem cell infusion
Radiation: 131I-MIBG
Radiation: Radiation therapy

First Posted Date: 2005-11-15

Last Posted Date: 2023-04-10

Lead Sponsor: Children's Hospital Los Angeles

Target Recruit Count: 50

Registration Number: NCT00253435

Locations: 🇺🇸
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
University of Chicago Comer Children's Hospital, Chicago, Illinois, United States

and more 12 locations

Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer

Phase 1

Completed

Conditions: Graft Versus Host Disease
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2005-11-04

Last Posted Date: 2010-09-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT00248430

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: therapeutic autologous lymphocytes
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: peripheral blood stem cell transplantation (PBSCT)

First Posted Date: 2005-10-27

Last Posted Date: 2015-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00244946

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: filgrastim
Drug: busulfan
Drug: melphalan
Drug: thiotepa
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2005-10-13

Last Posted Date: 2017-09-27

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 37

Registration Number: NCT00238433

Locations: 🇺🇸
Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: carmustine
Drug: cyclophosphamide
Drug: etoposide
Drug: melphalan
Procedure: autologous-autologous tandem hematopoietic stem cell transplantation
Radiation: radiation therapy

First Posted Date: 2005-10-06

Last Posted Date: 2018-03-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 98

Registration Number: NCT00233987

Locations: 🇺🇸
Cancer Center of Kansas, PA - Wellington, Wellington, Kansas, United States
🇺🇸
Associates in Womens Health, PA - North Review, Wichita, Kansas, United States
🇺🇸
Cancer Center of Kansas, PA - Parsons, Parsons, Kansas, United States

and more 50 locations

Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma

Phase 3

Completed

Conditions: Refractory Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: melphalan
Drug: amifostine trihydrate
Procedure: peripheral blood stem cell transplantation
Genetic: fluorescence in situ hybridization
Procedure: bone marrow ablation with stem cell support

First Posted Date: 2005-09-22

Last Posted Date: 2015-08-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 130

Registration Number: NCT00217438

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 1 locations

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Phase 3

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: BCNU
Drug: Cisplatinum
Drug: Melphalan
Drug: Ara-C
Drug: Etoposide
Drug: Dexamethasone
Drug: G-CSF
Procedure: stem cell harvest
Procedure: total body irradiation

First Posted Date: 2005-09-21

Last Posted Date: 2012-09-10

Lead Sponsor: European Mantle Cell Lymphoma Network

Target Recruit Count: 360

Registration Number: NCT00209222

Locations: 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪
German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱
The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

Phase 3

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-20

Last Posted Date: 2013-11-25

Lead Sponsor: Austrian Forum Against Cancer

Target Recruit Count: 212

Registration Number: NCT00205764

Locations: 🇦🇹
Wilhelminenspital, 1st Medical Department-center for oncology and hematology, Vienna, Austria

Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

First Posted Date: 2005-09-20

Last Posted Date: 2014-05-29

Lead Sponsor: University Hospital Tuebingen

Target Recruit Count: 61

Registration Number: NCT00202917

Locations: 🇩🇪
Center for Marrow Transplantation, Essen, Germany
🇩🇪
University of Wuerzburg Medical Center, Wuerzburg, Germany
🇩🇪
Deutsche Klinik für Diagnostik, Wiesbaden, Germany

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy